Search Results: (30 results)

The ENLACE study will learn more about colorectal cancer in Hispanic people so that treatment can be improved. Results may help your doctor choose your treatment and help you find out if you are eligible for a clinical trial. Your results may also help family members understand their cancer risks. 

The purpose of this research is to study and understand the genetic and molecular causes of breast and prostate cancer in people with African ancestry.

This study is testing a vaccine, known as the Nous-209 vaccine, which is intended to decrease the chances that people with Lynch syndrome will develop polyps that can turn into cancer.

This study is being done to assess the safety and effectiveness of a series of vaccines (Tri-Ad5), together with another drug (N-803) that magnifies the body’s response to vaccines, to see if there is an effect on the risk of developing colon and other cancers in LS patients.

This is a study to test the effectiveness of a drug (denosumab) on preventing the development of breast cancer in women with an inherited BRCA1 mutation.

Denosumab is a drug that is currently used to treat bone loss in order to reduce the risk of broken bones in healthy people, and is also used to reduce new bone growths in cancer patients whose cancer has spread to their bones. Research has shown that denosumab may also reduce the risk of developing breast cancer in women with an inherited BRCA1 mutation.

This study will compare robotic-assisted nipple sparing mastectomy (NSM) to standard surgery NSM for women with early-stage breast cancer. Eligible women will be randomly placed into one of two groups and either undergo the robotic-assisted procedure or undergo the standard of care open surgery for NSM. Participants will be followed for 5 years.

This study will create a system to assess an individual’s risk of breast cancer based on random sampling of normal breast tissue as well as determine new and help understand previously identified risk biomarkers.

PROMISE is a nationwide registry of prostate cancer patients with inherited mutations;screening approximately 5,000 participants with a prostate cancer diagnosis.

The PROMISE team is studying how these mutations affect patient outcomes.

The TAPUR Study aims to describe the safety and efficacy of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.

SOROCk [NRG-CC008] is a clinical trial studying if removal of just the fallopian tubes can reduce the risk of ovarian cancer nearly as much as removing both the ovaries and fallopian tubes among women with an inherited BRCA1 mutation. The main benefit of removing only the fallopian tubes and not the ovaries is to prevent surgically-induced menopause. The study will also examine various patient-reported quality of life outcomes. Researchers believe that most ovarian cancers first begin in the fallopian tubes, suggesting that removing the fallopian tubes only may prevent the development of ovarian cancer. This concept has never been formally testing in a clinical trial.

We're looking into how families share information among Caribbean individuals who have a genetic mutation linked to an increased risk of cancer. The goal is to understand the experiences of Caribbean people dealing with a higher chance of developing cancer. This study will help us figure out how genetic counselors can better support Caribbean patients and their family members in handling this genetic information. If you're interested, you can participate by filling out a survey. If you're eligible, we might reach out to you for a 45-60 minute interview. 

This study will compare a combination of drugs for people who have HER2-positive colorectal cancer who have not yet received treatment in the metastatic setting.

We hope to understand women’s preferences about the benefits and effects of cancer-preventing surgeries. In this survey of women ages 25-50 with an inherited BRCA1 or BRCA2 mutation and no personal history of cancer, we present scenarios and ask participants to make hypothetical choices. Your responses will help us to design educational tools for people who are at high risk of breast and ovarian cancer who face personal decisions about cancer prevention.

This study will look at a new vaccine known as INO-5401 used alone or combined with a second vaccine called INO-9012. The study will test if the vaccine is safe (without large side effects) and test a new way of giving vaccines. It will also test whether the vaccine activates the immune system. A goal of this research is to reduce cancer risk in people with a BRCA1 or BRCA2 mutation. Additional studies will be needed to learn if this vaccine approach lowers cancer risk in mutation carriers. 

This study is for families with patients that have newly-diagnosed advanced cancer. African American family caregivers and family caregivers living in rural communities will be eligible.

A free research program offering mindfulness, coping, and healthy lifestyle skills for ovarian cancer survivors. 

The National Institutes of Health has a clinical trial for men at high genetic risk for prostate cancer. This is trial is for men without prostate cancer, ages 30 to 75, who have tested positive for Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or FANC (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, and FANCM). The trial involves screening MRI of the prostate every two years and biopsy of the prostate if the MRI is abnormal. There is no cost for travel or study-related tests. 

This study will colect blood and stool samples to detect colorectal cancer or precancerous polyps in people with Lynch syndrome.

Screening study for women at risk for breast cancer due to an inherited mutation or other risk factor

This study will test three different diets in people who are overweight and who have an increased risk of colorectal cancer. The study will look at whether these diets improve eating and possibly lead to weight loss. 

This study will teach Latinas with a high risk of breast cancer about how diet, exercise, ethnicity, genetics and screening and prevention guidelines may impact their likelihood for developing breast cancer.

This study is looking at the effectiveness of combining a PARP inhibitor called niraparib and an immunotherapy called dostarlimab for treating people with an inherited BRCA mutation (found with genetic testing) or a tumor mutation (found through tumor testing) who have breast, pancreatic, ovarian, fallopian tube or primary peritoneal cancer that is metastatic or advanced and cannot be removed by surgery (unresectable).

This study will test the safety and effectiveness of using a new immunotherapy drug called NC410 to treat people with different types of metastatic or advanced cancers.

Relationships, Intimacy, and Self-Esteem among Sexual and Gender Minority Cancer Survivors (RISE) is a research study that focuses on the experiences of 18-39-year-old sexual and/or gender minority cancer survivors. Participants will be asked to complete an interview on relationships, self-esteem, and intimacy.

This study is being done to learn about the effects of using three study medicines together as treatment for metastatic colorectal cancer that has been previously untreated.

The goal of this study is to identify whether Li-Fraumini syndrome (LFS), which has a high lifetime cancer risk, has any other causes besides the TP53 mutation.

Researchers are conducting an online survey to look into the personal experiences of people who received reclassfied genetic testing results for hereditary cancer gene mutations. 

This study is comparing safety and effectiveness of a new drug called giredestrant compared to standard hormone therapy in people with early-stage, ER-positive breast cancer. 

This study will determine if prostate magnetic resonance imaging (MRI) will find prostate cancer in men at high risk of developing prostate cancer.

Our goal is to understand the experiences of people with intellectual disability in regard to screening for cancer, for example colonoscopies for colon cancer and mammograms for breast cancer. For people not being screened, we hope to learn about any barriers faced.